

# Special Issue

## Primary Hepatobiliary Tumor

### Message from the Guest Editors

Recently, much progress has been made in the treatment of primary hepatobiliary malignancy, from systemic therapy to local treatment. Basis research, as well as clinical studies, have contributed to the success of multidisciplinary hepatobiliary cancer care. While excellent survival rates have been reported following liver transplantation for early-stage hepatocellular carcinoma or perihilar cholangiocarcinoma, the survival rate in patients with advanced disease remains unsatisfying, despite the implementation of immunotherapy. Research to explore the mechanisms of carcinogenesis, and to identify new treatment targets and strategy, is encouraged. Here, we welcome papers with a focus on primary hepatobiliary tumor.

---

### Guest Editors

Prof. Dr. Jakob Izbicki

Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Dr. Jun Li

Department of General, Visceral and Thorax Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

---

### Deadline for manuscript submissions

closed (30 November 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/72958](https://mdpi.com/si/72958)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)